Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756208 · ClinicalTrials.gov registry record · Phase 1
A Safety and Immunogenicity Trial of IHV01
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT02756208: Completed Phase 1 study, sponsored by University of Maryland, Baltimore.
NCT02756208 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 65 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02756208, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers (Human Immunodeficiency Virus-1 uninfected).
Primary Outcome
Signs and symptoms include pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and maximum severity of systemic symptoms.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL 300 ug FLSC vaccine
- BIOLOGICAL 150 ug FLSC vaccine
- BIOLOGICAL 75 ug FLSC vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
What the finished NCT02756208 record still lists
NCT02756208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02756208 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02756208 about?
NCT02756208 is a clinical study titled "A Safety and Immunogenicity Trial of IHV01". This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers (Human Immunodeficiency Virus-1 uninfected).
What is the current status of trial NCT02756208?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2015-11. Estimated completion is 2018-07.
What interventions are being tested in trial NCT02756208?
The interventions under investigation include: Placebo (BIOLOGICAL), 300 ug FLSC vaccine (BIOLOGICAL), 150 ug FLSC vaccine (BIOLOGICAL), 75 ug FLSC vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02756208?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02756208's enrollment target sits among peer trials
65 798th of 2000 higher than 1,193 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia